logo

AMLX

Amylyx·NASDAQ
--
--(--)
--
--(--)

AMLX fundamentals

Amylyx (AMLX) released its earnings on Mar 3, 2026: revenue was 0 (YoY +100.00%), beat estimates; EPS was -0.3 (YoY +45.45%), beat estimates.
Revenue / YoY
0
+100.00%
EPS / YoY
-0.3
+45.45%
Report date
Mar 3, 2026
AMLX Earnings Call Summary for Q4,2025
  • Avexitide Milestone: Pivotal LUCIDITY trial nearing completion, with 160,000 U.S. PBH patients as target market.
  • Financial Strength: $317M cash runway to 2028; 8% YoY expense reduction supports R&D focus.
  • Pipeline Expansion: AMX0318 development candidate nominated; AMX0114 Phase I progressing safely.
  • Market Validation: High recruitment rates and physician engagement underscore PBH's unmet need.
EPS
Revenue

Revenue & Expenses

Key Indicators

Amylyx (AMLX) key financial stats and ratios, covering profitability, financial health, and leverage.
Amylyx (AMLX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Amylyx (AMLX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Amylyx (AMLX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Amylyx (AMLX) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Amylyx (AMLX) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield